These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

91 related items for PubMed ID: 22314422

  • 1. Decreased infectivity of nucleoside analogs-resistant hepatitis B virus mutants.
    Billioud G, Pichoud C, Parent R, Zoulim F.
    J Hepatol; 2012 Jun; 56(6):1269-75. PubMed ID: 22314422
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir.
    Brunelle MN, Jacquard AC, Pichoud C, Durantel D, Carrouée-Durantel S, Villeneuve JP, Trépo C, Zoulim F.
    Hepatology; 2005 Jun; 41(6):1391-8. PubMed ID: 15915463
    [Abstract] [Full Text] [Related]

  • 6. Analysis of the cytosolic domains of the hepatitis B virus envelope proteins for their function in viral particle assembly and infectivity.
    Blanchet M, Sureau C.
    J Virol; 2006 Dec; 80(24):11935-45. PubMed ID: 17020942
    [Abstract] [Full Text] [Related]

  • 7. Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the "fingers" subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene.
    Torresi J, Earnest-Silveira L, Civitico G, Walters TE, Lewin SR, Fyfe J, Locarnini SA, Manns M, Trautwein C, Bock TC.
    Virology; 2002 Jul 20; 299(1):88-99. PubMed ID: 12167344
    [Abstract] [Full Text] [Related]

  • 8. Impact of hepatitis B e antigen-suppressing mutations on the replication efficiency of entecavir-resistant hepatitis B virus strains.
    Amini-Bavil-Olyaee S, Herbers U, Luedde T, Trautwein C, Tacke F.
    J Viral Hepat; 2011 Nov 20; 18(11):804-14. PubMed ID: 20887378
    [Abstract] [Full Text] [Related]

  • 9. Failure of the lamivudine-resistant rtM204I hepatitis B virus mutants to efficiently support hepatitis delta virus secretion.
    Vietheer PT, Netter HJ, Sozzi T, Bartholomeusz A.
    J Virol; 2005 May 20; 79(10):6570-3. PubMed ID: 15858045
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The YMDD and rtA194T mutations result in decreased replication capacity in wild-type HBV as well as in HBV with precore and basal core promoter mutations.
    Zhu Y, Curtis M, Borroto-Esoda K.
    Antivir Chem Chemother; 2011 Aug 23; 22(1):13-22. PubMed ID: 21860069
    [Abstract] [Full Text] [Related]

  • 12. Development of HBV S gene mutants in chronic hepatitis B patients receiving nucleotide/nucleoside analogue therapy.
    Yeh CT.
    Antivir Ther; 2010 Aug 23; 15(3 Pt B):471-5. PubMed ID: 20516567
    [Abstract] [Full Text] [Related]

  • 13. In vitro inhibition of HBV replication by a novel compound, GLS4, and its efficacy against adefovir-dipivoxil-resistant HBV mutations.
    Wang XY, Wei ZM, Wu GY, Wang JH, Zhang YJ, Li J, Zhang HH, Xie XW, Wang X, Wang ZH, Wei L, Wang Y, Chen HS.
    Antivir Ther; 2012 Aug 23; 17(5):793-803. PubMed ID: 22668794
    [Abstract] [Full Text] [Related]

  • 14. Long-term follow-up of chronic hepatitis B after the emergence of mutations in the hepatitis B virus polymerase region.
    Natsuizaka M, Hige S, Ono Y, Ogawa K, Nakanishi M, Chuma M, Yoshida S, Asaka M.
    J Viral Hepat; 2005 Mar 23; 12(2):154-9. PubMed ID: 15720530
    [Abstract] [Full Text] [Related]

  • 15. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient.
    Villet S, Ollivet A, Pichoud C, Barraud L, Villeneuve JP, Trépo C, Zoulim F.
    J Hepatol; 2007 Mar 23; 46(3):531-8. PubMed ID: 17239478
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Supportive role played by precore and preS2 genomic changes in the establishment of lamivudine-resistant hepatitis B virus.
    Ohkawa K, Takehara T, Kato M, Deguchi M, Kagita M, Hikita H, Sasakawa A, Kohga K, Uemura A, Sakamori R, Yamaguchi S, Miyagi T, Ishida H, Tatsumi T, Hayashi N.
    J Infect Dis; 2008 Oct 15; 198(8):1150-8. PubMed ID: 18713056
    [Abstract] [Full Text] [Related]

  • 18. Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV.
    Yang H, Qi X, Sabogal A, Miller M, Xiong S, Delaney WE.
    Antivir Ther; 2005 Oct 15; 10(5):625-33. PubMed ID: 16152756
    [Abstract] [Full Text] [Related]

  • 19. The oncogenic potential of hepatitis B virus rtA181T/ surface truncation mutant.
    Lai MW, Yeh CT.
    Antivir Ther; 2008 Oct 15; 13(7):875-9. PubMed ID: 19043921
    [Abstract] [Full Text] [Related]

  • 20. The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound.
    Warner N, Locarnini S.
    Hepatology; 2008 Jul 15; 48(1):88-98. PubMed ID: 18537180
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.